MDxHealth SA (NASDAQ:MDXH) Receives Consensus Rating of “Hold” from Analysts

MDxHealth SA (NASDAQ:MDXH) has received a consensus rating of “Hold” from the five analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $2.8333.

Several research analysts have recently issued reports on the company. Wall Street Zen raised MDxHealth to a “sell” rating in a research note on Saturday. TD Cowen reissued a “buy” rating and issued a $1.50 price objective (down from $7.00) on shares of MDxHealth in a research note on Thursday, May 14th. Lake Street Capital set a $3.00 target price on shares of MDxHealth and gave the company a “buy” rating in a report on Friday. William Blair cut shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, BTIG Research reduced their price target on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, May 14th.

MDxHealth News Summary

Here are the key news stories impacting MDxHealth this week:

• Positive Sentiment: MDxHealth reported second-quarter revenue of $27.2 million, up 16% year over year and above the approximately $26.1 million analyst estimate. The company’s $0.18 per-share loss was slightly better than the $0.19 consensus cited by MarketBeat, although another estimate tracked by Zacks showed a larger expected loss of $0.12. MDxHealth Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised or reaffirmed an optimistic FY 2026 revenue outlook of $110 million to $115 million, well above the roughly $98.8 million consensus estimate. This suggests management expects continued commercial momentum. MDxHealth Earnings Report
• Positive Sentiment: Management discussed the results and outlook during its second-quarter earnings call, giving investors additional detail on the company’s operating performance and growth plans. MDxHealth Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Trading in MDXH was temporarily paused several times under the exchange’s Limit Up-Limit Down mechanism. The halts do not represent a fundamental company announcement, but they underscore unusually high volatility and speculative trading activity.
• Negative Sentiment: MDxHealth agreed to raise $20 million through a direct share offering. The added funding may support operations and growth, but issuing new shares can dilute existing shareholders and may be contributing to the sharp price swings. MDxHealth Raises $20 Million in Direct Share Offering

MDxHealth Stock Performance

Shares of MDXH stock opened at $0.81 on Friday. The stock has a fifty day moving average price of $0.47 and a 200 day moving average price of $1.78. The stock has a market cap of $40.00 million, a PE ratio of -1.12 and a beta of 1.42. MDxHealth has a 1 year low of $0.40 and a 1 year high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. The firm had revenue of $27.21 million for the quarter, compared to analysts’ expectations of $26.14 million. As a group, equities research analysts predict that MDxHealth will post -0.6 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MDXH. Perkins Capital Management Inc. grew its holdings in MDxHealth by 7.1% during the 1st quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after buying an additional 97,500 shares during the last quarter. Kennedy Capital Management LLC purchased a new position in MDxHealth during the third quarter worth $1,826,000. FreeGulliver LLC raised its holdings in shares of MDxHealth by 25.7% in the fourth quarter. FreeGulliver LLC now owns 317,894 shares of the company’s stock worth $1,135,000 after acquiring an additional 65,000 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of MDxHealth by 21.8% in the first quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock worth $701,000 after acquiring an additional 54,600 shares during the last quarter. Finally, Mink Brook Asset Management LLC lifted its position in shares of MDxHealth by 64.9% in the fourth quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock valued at $940,000 after acquiring an additional 103,686 shares in the last quarter.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.